NCT06908304Phase 3Recruiting

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-07-31Estimated

Enrollment · participants300Estimated

Source updated2026-01-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-12 · 2 fields changed

Primary completion date changed

− Before

~~29 Jul 2026~~

+ After

31 Jul 2027

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Carcinoma, Non-Small -Cell Lung

Treatments or interventions studied

6-Thio-2'-DeoxyguanosineDrugAlso known as 6-thio-dG, THIO, ateganosine
CemiplimabDrugAlso known as LIBTAYO®
DocetaxelDrugAlso known as Taxotere, Docecad
VinorelbineDrugAlso known as Navelbine, Vinorelbine tartrate
Gemcitabine aloneDrugAlso known as Gemzar

Primary outcomes · main study measures

measure: Overall Survival; description: Overall survival as defined as the time from randomization to death from any cause.; timeFrame: Within 2 Years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history